Impact of antimicrobial multidrug resistance on inpatient care cost: An evaluation of the evidence

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 3, 2013, Pages 321-331

  Tansarli, Giannoula S ^a   Karageorgopoulos, Drosos E ^a,b   Kapaskelis, Anastasios ^a   Falagas, Matthew E ^a,c,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

^c MITERA HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carbapenem resistant; costs; economic impact; extended spectrum b lactamase; hospital charges; methicillin resistant Staphylococcus aureus; multidrug resistance

Indexed keywords

ACINETOBACTER BAUMANNII; BACTERIAL INFECTION; COST BENEFIT ANALYSIS; COST OF ILLNESS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEALTH CARE COST; HOSPITAL CARE; HOSPITAL COST; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; REVIEW; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; HOSPITAL COSTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84874598748     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.4     Document Type: Review

References (39)

1. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum b-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J. Antimicrob. Chemother. 67(6), 1311-1320 (2012).
2. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60(5), 913-920 (2007).
3. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27(9), 893-900 (2006).
4. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bactere-mia with extended-spectrum-b-lactamase- producing Enterobacteriaceae. Antimicrob. Agents Chemother. 50(4), 1257-1262 (2006).
5. Giske CG, Monnet DL, Cars O, Carmeli Y; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob. Agents Chemother. 52(3), 813-821 (2008).
6. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin. Infect. Dis. 46(7), 1121-1122 (2008).
7. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard defnitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268-281 (2012).
8. Hu B, Ye H, Xu Y et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum b-lactamase (ESBL) producing bacteria in China. Curr. Med. Res. Opin. 26(6), 1443-1449 (2010).
9. Kola A, Maciejewski O, Sohr D, Ziesing S, Gastmeier P. Clinical impact of infections caused by ESBL-producing E. coli and K. pneumoniae. Scand. J. Infect. Dis. 39(11-12), 975-982 (2007).
10. Rubio-Terrés C, Garau J, Grau S, Martinez-Martinez L; Cast of Resistance Study group. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-suscep-tible Staphylococcus aureus in Spain: a retrospective cohort study. Clin. Microbiol Infect. 16(6), 722-728 (2010).
11. Anderson DJ, Kaye KS, Chen LF et al Clinical and fnancial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS ONE 4(12), e8305 (2009).
12. Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 29(7), 671-674 (2008).
13. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resist ant Staphylococcus aureus bloodstream infection and those with methicillin-sus-ceptible S. aureus bloodstream infection? Infect. Control Hosp. Epidemiol. 30(5), 453-460 (2009).
14. Boyce JM, Landry M, Deetz TR, DuPont HL. Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections. Infect. Control 2(2), 110-116 (1981).
15. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol 26(2), 166-174 (2005).
16. Filice GA, Nyman JA, Lexau C et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect. Control Hosp. Epidemiol. 31(4), 365-373 (2010).
17. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and-resistant Staphylococcus aureus infections. Ann. Pharmacother. 38(9), 1377-1382 (2004).
18. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32(8), 1162-1171 (2001).
19. Lautenbach E, Synnestvedt M, Weiner MG et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect. Control Hosp. Epidemiol 30(12), 1186-1192 (2009).
20. Lautenbach E, Synnestvedt M, Weiner MG et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31(1), 47-53 (2010).
21. Lee NY, Lee HC, Ko NY et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect. Control Hosp. Epidemiol. 28(6), 713-719 (2007).
22. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum b-lactamase-producing Escheri chia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect. Control Hosp. Epidemiol. 27(11), 1226-1232 (2006).
23. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 52(2), 113-122 (2005).
24. Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection 39(2), 141-147 (2011).
25. Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J. Arthroplasty 25(6 Suppl), 103-107 (2010).
26. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerging Infect. Dis. 5(1), 9-17 (1999).
27. Taneja C, Haque N, Oster G et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. J. Hosp. Med. 5(9), 528-534 (2010).
28. Tumbarello M, Spanu T, Di Bidino R et al. Costs of bloodstream infections caused by Escherichia coli and infuence of extended-spectrum-b-lactamase production and inadequate initial antibiotic therapy. Antimicrob. Agents Chemother. 54(10), 4085-4091 (2010).
29. Yang YS, Ku CH, Lin JC et al. Impact of extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J. Microbiol. Immunol. Infect. 43(3), 194-199 (2010).
30. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococ-cus aureus surgical site infection. Clin. Infect. Dis. 36(5), 592-598 (2003).
31. Lepelletier D, Ferréol S, Villers D, Richet H. Methicillin-resistant Staphylococcus aureus nosocomial infections in ICU: risk factors, morbidity and cost. Pathol. Biol. 52(8), 474-479 (2004).
32. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect. Control Hosp. Epidemiol. 25(5), 425-430 (2004).
33. Mejía Villatoro CR, Villatoro Nazareno G, Silvestre M, de Briz H, Valle R, Gordillo MR. Costo del tratamiento de infecciones nosocomiales por gérmenes multiresist-entes, Hospital Roosevelt, Guatemala. Rev. Panam. Infectol. 10(4 Suppl. 1), S96-S100 (2008).
34. Ott E, Bange FC, Reichardt C et al. Costs of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 76(4), 300-303 (2010).
35. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 30(8), 746-752 (2009).
36. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resist-ant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. 26(2), 175-183 (2005).
37. Greiner W, Rasch A, Köhler D, Salzberger B, Fätkenheuer G, Leidig M. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clin. Microbiol. Infect. 13(3), 264-268 (2007).
38. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin. Infect. Dis. 43(3), 389; author reply 389-389; author reply 390 (2006).
39. Blot S, Vandijck D, Lizy C, Annemans L, Vogelaers D. Estimating the length of hospitalization attributable to multidrug antibiotic resistance. Antimicrob. Agents Chemother. 54(9), 4046; author reply 4046-4046; author reply 4047 (2010).